On March 11, 2026, LeMaitre Vascular (NASDAQ:LMAT) Senior Vice President, Operations, Trent G Kamke, reported the exercise and immediate sale of 2,625 shares of common stock for total proceeds of approximately $285,000, according to this SEC Form 4 filing.
|
Metric |
Value |
Context |
|---|---|---|
|
Shares sold (direct) |
2,625 |
Open-market shares sold (code ‘S’) in this filing |
|
Transaction value |
$284,812.50 |
Based on SEC Form 4 weighted average purchase price ($108.50) |
|
Post-transaction shares (direct) |
6,677 |
Directly held shares after transaction completion |
|
Post-transaction value (direct ownership) |
~$722,000 |
Based on March 11, 2026 market close |
Transaction value based on SEC Form 4 weighted average purchase price ($108.50); post-transaction value based on March 11, 2026, market close.
-
What was the structure and rationale for the transaction?
The trade reflects an exercise of 2,625 vested options immediately followed by a direct sale of the common shares, a common mechanism for executives to monetize equity awards while maintaining compliance with company trading policies. -
How did this transaction impact Kamke’s ownership stake?
Direct common stock holdings decreased from approximately 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure; no indirect holdings were involved or remain post-transaction. -
How does the trade fit within Kamke’s recent activity?
This transaction matches the recent period’s median sell size (2,625 shares) and percentage of holdings sold per trade (28.22%), indicating consistency in liquidation cadence as available direct holdings have declined over time. -
What continuing equity exposure does Kamke retain?
Kamke continues to hold 1,353 directly owned stock options, which can be exercised for additional common shares in the future, preserving potential upside alignment with company performance.
|
Metric |
Value |
|---|---|
|
Revenue (TTM) |
$249.6 million |
|
Net income (TTM) |
$57.7 million |
|
Dividend yield |
0.99% |
|
1-year price change |
32.90% |
* 1-year price change calculated using March 11, 2026, as the reference date.
-
Offers a portfolio of medical devices and implants for the treatment of peripheral vascular disease, including angioscopes, embolectomy and thrombectomy catheters, carotid shunts, vascular grafts, and closure systems.
-
Generates revenue primarily through direct sales and distributor relationships, focusing on proprietary vascular products designed for surgical intervention and vascular repair.
-
Serves hospitals, surgeons, and healthcare providers treating vascular disease, with a global customer base spanning North America, Europe, and other international markets.
